Powered By
METHYLTRANSFERASE INHIBITOR
|
Tazverik was voluntarily pulled from the U.S. market in March 2026 following a request from the U.S. Food and Drug Administration (FDA). New safety data from a confirmatory clinical trial showed an increased risk of secondary hematologic malignancies (additional blood cancers), raising concerns that the drug’s risks may outweigh its benefits. Read more about the withdrawal. If you’re currently taking this medication, talk to your healthcare provider about safe options for transitioning to a different treatment. |
Overview
Tazverik was a prescription drug approved by the FDA to treat follicular lymphoma in adults and children 16 years and older whose tumors were positive for the EZH2 mutation and who had received two previous therapies. Tazverik was also referred to by its drug name, tazemetostat.
Tazverik was a methyltransferase inhibitor. Tazverik was believed to work by blocking the EZH2, which may prevent cancer cells from growing.
How was it taken?
Tazverik was generally taken orally twice a day. Tazverik came in the form of a tablet.
Side effects
The FDA-approved label for Tazverik listed common side effects including pain, fatigue, nausea, abdominal pain, cough, and upper respiratory tract infections.
Rare but serious side effects listed for Tazverik included developing secondary cancers.
For more details about this treatment, visit:
Become a member to get even more
Join
